Sartorius AG

1SRT3

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    14,242

Stocks News & Analysis

stocks

Pure-play data center share raises capital to fund AI demand

Funding the next wave of data center growth.
stocks

Chart of the Week: BHP’s growth story faces a reality check

China’s slowing economy could weigh on BHP’s future growth.
stocks

3 best ASX growth stocks to buy for the long term

Here’s three high-quality growth companies with wide moats.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,978.8034.20-0.38%
CAC 408,338.8139.05-0.47%
DAX 4024,830.9884.51-0.34%
Dow JONES (US)52,146.42406.55-0.77%
FTSE 10010,600.3728.130.27%
HKSE24,562.24446.36-1.78%
NASDAQ25,520.24361.70-1.40%
Nikkei 22564,141.122,694.42-4.03%
NZX 50 Index13,694.6879.900.59%
S&P 5007,457.6976.08-1.01%
S&P/ASX 2008,796.7020.10-0.23%
SSE Composite Index3,764.15118.26-3.05%

Market Movers